Therapeutic Areas: Cardiology

Choose Therapeutic Area
Oncology
Cardiology
Ophthalmology
Neurology
Endocrinology
Gastroenterology
Dermatology
Urology
Infectious diseases incl. Covid-19
Psychiatry
Rare diseases
Cromos Pharma has extensive experience in cardiovascular and cardiometabolic space across the entire drug development spectrum

Despite the advances in the cardiometabolic field over the past 20 years, cardiovascular and metabolic diseases remain the leading causes of morbidity and mortality worldwide. The need to discover and develop better, safer, and more cost-effective drugs and devices remains.

Cromos Pharma has 19 years of experience conducting cardiovascular research with a particular emphasis on key cardiovascular and metabolic indications. We have both scientific and clinical expertise to support a wide array of cardiology studies, from early to late phase, and with single- or multi-country execution strategies. By leveraging our international expertise, we deliver unparallel results through diligent feasibility analysis, rapid startup and accelerated recruitment, while utilizing proactive risk management strategies and maintaining the highest data quality.

Our team has vast expertise in organizing scientific advisory board meetings of academic and clinical cardiologists and KOLs.

Our cardiovascular experience includes:
    • Acute heart failure
    • Angina pectoris
    • Aortic valve surgery
    • Atrial fibrillation
    • Cardiac Arrhythmias
    • Cardiothoracic surgery
    • Congestive heart failure (HFrEF and (HFpEF)
    • Chronic venous insufficiency
    • Congenital heart disease
    • Coronary artery disease
    • Deep vein thrombosis
    • Dyslipidemia
    • Hypertension
    • Hyperlipidemia
    • Ischemic heart disease
    • Myocardial Infarction
    • Pericarditis
    • Peripheral arterial disease
    • Pulmonary hypertension
    • Valvular Heart Diseases
    • Varicose veins (chronic venous disease)
    • Venous thromboembolism (VTE)
Cromos Pharma Cardiology experience in the last five years
19,000
Patients
50
Studies
3,000
Clinical Sites
our Success story
Phase III Multi-Center trial in Angina Pectoris
Click to openclose
Why Cromos Pharma
  • We are the only CRO to offer “No Patients, No Payment” risk sharing program, where the sponsor pays only if we deliver on our milestones.
  • We have the scientific and clinical expertise to support your clinical studies, from early to late phase, from single- to multi-country execution strategies.
  • By leveraging our international expertise, we deliver unparalleled results through diligent feasibility analysis, rapid startup, and accelerated recruitment, while utilizing proactive risk management strategies and maintaining the highest data quality.
  • Our team has vast expertise in organizing scientific advisory board meetings of key opinion leaders, clinicians, and industry stakeholders.

TO FIND OUT MORE

INQUIRY@CROMOSPHARMA.COM

more therapeutics